Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China

• Main Authors: Xiaoyu Zhang (Author), Xiongxiong Fan (Author), Jin Zhang (Author), Fengli Jiang (Author), Yiping Wu (Author), Beibei Yang (Author), Xinghuan Li (Author), Dong Liu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundTislelizumab is the first PD-1 inhibitor in China to demonstrate superior efficacy in second-line or third-line treatment of patients with advanced or metastatic non-small-cell lung cancer (NSCLC). This study aimed to evaluate the cost-effectiveness of tislelizumab compared to docetaxel fr...